Opko to Purchase OURLab CLIA Lab to Support US Launch of 4Kscore Prostate Cancer Dx | GenomeWeb

Opko Health has entered a definitive agreement to acquire Prost-Data, which does business as OURLab, a Nashville, Tenn.-based CLIA laboratory.

The acquisition will provide Opko with a platform to support the US commercial launch of its 4Kscore protein biomarker prostate cancer test, the company said. Opko is planning a "near-term" US launch of the test as a laboratory-developed test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.